Discussion
Gain Therapeutics’ oral therapy candidate rexaceract, formerly called GT-02287, stabilized motor symptoms in a small group of people with Parkinson’s disease who were treated for one year. That’s according to new data from an open-label extension of an early clinical trial, which showed no meaningful progression of Parkinson’s…
